A commons for leftover trial biospecimens with standard access for approved research
Blood and tissue samples collected in cancer trials are the best material for validating new tests, but most sit unused under contracts that make access impossible. A commons would make them available for approved research.
Sponsors and academic trial groups deposit or catalogue residual biospecimens from completed trials (with linked clinical outcomes) in a federated commons with a single access committee, standard consent language for future trials that permits secondary research, and cost-recovery pricing. Access priority goes to biomarker validation studies and to negative-trial samples that can explain why drugs failed. The NCI's cooperative group banks and the EORTC's SPECTA show the model at small scale; the change is universal deposit obligations and one door to knock on.
- Secrecy and intellectual property block collaboration · Companies with complementary drugs rarely test them together, and data that could answer questions stays locked up.
- Biomarkers are not validated or standardised · Tests that decide who gets a drug are often not validated prospectively and are measured differently in every lab.
Pages like this
not linked directly; found by shared links- IdeaA public biomarker validation utility with pre-diagnostic biobanks and blinded testing
Shares Proteomics & phosphoproteomics, Biomarkers are not validated or standardised, Liquid biopsy (ctDNA).
- IdeaA blood test for the pre-metastatic niche
Shares Proteomics & phosphoproteomics, Biomarkers are not validated or standardised, Liquid biopsy (ctDNA).
- IdeaAn antitrust safe harbour for cross-company combination trials and data pooling
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
- IdeaA public registry of stalled academic assets and shelved company compounds
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
- IdeaA shared library of pooled control arms to shrink and speed future trials
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.
- ProductFoundationOne CDx / Liquid CDx
Shares Companion diagnostics, Biomarkers are not validated or standardised, Liquid biopsy (ctDNA).
- IdeaA reliance pathway for companion diagnostics so the test arrives with the drug
Shares Companion diagnostics, Biomarkers are not validated or standardised.
- IdeaA federated learning consortium of cancer centres that jointly own the models
Shares A single oncology trial data trust with mandatory deposit within eighteen months, Secrecy and intellectual property block collaboration.